Marshall Wace, LLP Roivant Sciences Ltd. Transaction History

Marshall Wace, LLP

$74.4 Billion
Q1 2025

A detailed history of Marshall Wace, LLP transactions in Roivant Sciences Ltd. stock. As of the latest transaction made, Marshall Wace, LLP holds 271,823 shares of ROIV stock, worth $3.06 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

271,823

Previous 2,946,954 90.78%

Holding current value

$3.06 Million

Previous $34.9 Million 92.13%

% of portfolio

0.0%

Previous 0.04%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	SELL	$10.09 - $12.08 $27 Million - $32.3 Million	-2,675,131 Reduced 90.78%	271,823 $2.74 Million
Q4 2024 Feb 13, 2025	BUY	$11.16 - $12.71 $16.8 Million - $19.1 Million	1,505,062 Added 104.38%	2,946,954 $34.9 Million
Q3 2024 Nov 14, 2024	BUY	$10.17 - $12.5 $7.39 Million - $9.09 Million	727,132 Added 101.73%	1,441,892 $16.6 Million
Q2 2024 Aug 14, 2024	BUY	$10.36 - $11.74 $6.84 Million - $7.76 Million	660,660 Added 1221.18%	714,760 $7.56 Million
Q1 2024 May 15, 2024	SELL	$9.87 - $11.8 $1.8 Million - $2.16 Million	-182,743 Reduced 77.16%	54,100 $570,000
Q4 2023 Feb 14, 2024	BUY	$8.38 - $11.58 $1.98 Million - $2.74 Million	236,843 New	236,843 $2.66 Million
Q2 2023 Aug 14, 2023	BUY	$7.09 - $10.08 $7.75 Million - $11 Million	1,093,255 Added 364.84%	1,392,906 $14 Million
Q1 2023 May 15, 2023	BUY	$6.92 - $9.98 $1.73 Million - $2.5 Million	250,670 Added 511.77%	299,651 $2.21 Million
Q4 2022 Feb 14, 2023	SELL	$3.36 - $7.99 $317,291 - $754,511	-94,432 Reduced 65.85%	48,981 $391,000
Q3 2022 Nov 14, 2022	BUY	$0.51 - $4.84 $73,140 - $694,118	143,413 New	143,413 $461,000

Others Institutions Holding ROIV

# of Institutions

332

Shares Held

496M

Call Options Held

3.67M

Put Options Held

754K

View Full List

About Roivant Sciences Ltd.

Ticker ROIV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 704,382,976
Market Cap $7.92B
Description
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...

More about ROIV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account

Marshall Wace, LLP Roivant Sciences Ltd. Transaction History